{"slug":"genetics","tag":"genetics","variants":["genetics"],"description":"No description yet","count":9,"kinds":{"person":9},"related":[{"slug":"clinician-scientist","tag":"clinician-scientist","shared":5},{"slug":"leadership","tag":"leadership","shared":3},{"slug":"prevention","tag":"prevention","shared":2},{"slug":"uk","tag":"uk","shared":2},{"slug":"breast","tag":"breast","shared":1},{"slug":"colorectal","tag":"colorectal","shared":1},{"slug":"dermatology","tag":"dermatology","shared":1},{"slug":"paediatric-oncology","tag":"paediatric oncology","shared":1},{"slug":"paediatrics","tag":"paediatrics","shared":1},{"slug":"policy","tag":"policy","shared":1},{"slug":"prostate","tag":"prostate","shared":1},{"slug":"screening","tag":"screening","shared":1}],"records":[{"id":"john-burn","kind":"person","name":"John Burn","route":"/people/john-burn/","tldr":"The Newcastle geneticist whose CAPP2 trial showed that two years of aspirin cuts bowel cancer in people born with Lynch syndrome, a result that still shapes NHS advice."},{"id":"ros-eeles","kind":"person","name":"Rosalind Eeles","route":"/people/ros-eeles/","tldr":"The oncogeneticist who found most of the common genetic variants that raise a man's risk of prostate cancer, and whose work is the reason the UK's first prostate screening programme is defined by a gene rather than by an age."},{"id":"ronald-cohn","kind":"person","name":"Ronald Cohn","route":"/people/ronald-cohn/","tldr":"Clinical geneticist who leads The Hospital for Sick Children in Toronto, one of the world's largest paediatric academic health centres."},{"id":"eli-sprecher","kind":"person","name":"Eli Sprecher","route":"/people/eli-sprecher/","tldr":"Dermatologist and geneticist who has been chief executive of Tel Aviv Sourasky Medical Center, a major Israeli academic hospital, since 2024."},{"id":"brandon-wainwright","kind":"person","name":"Brandon Wainwright","route":"/people/brandon-wainwright/","tldr":"Geneticist known for work on the genetic drivers of childhood brain cancer who became Director and CEO of QIMR Berghofer, a leading Australian medical research institute, in 2026."},{"id":"ephrat-levy-lahad","kind":"person","name":"Ephrat Levy-Lahad","route":"/people/ephrat-levy-lahad/","tldr":"Produced the evidence that made Israel the first country to offer BRCA testing to a whole population group, by measuring cancer risk in carriers found through healthy men rather than through cancer clinics."},{"id":"rachel-michaelson-cohen","kind":"person","name":"Rachel Michaelson-Cohen","route":"/people/rachel-michaelson-cohen/","tldr":"Led the work of turning nine Israeli high-risk clinics, which were each doing something different, into one national protocol for looking after the carriers the screening programme keeps finding."},{"id":"eitan-friedman","kind":"person","name":"Eitan Friedman","route":"/people/eitan-friedman/","tldr":"Mapped which inherited cancer variants recur in which Israeli communities, and showed that outside the Ashkenazi founder panel there is no shortcut: you have to sequence."},{"id":"mark-robson","kind":"person","name":"Mark E. Robson","route":"/people/mark-robson/","tldr":"New York breast oncologist and cancer geneticist who led OlympiAD, the trial that made olaparib the first PARP inhibitor approved for BRCA-mutated breast cancer."}]}